Back to the Future: Clinical Experience with and Access to Lipid-Lowering Agents of the Past, Present, and Future

2.00 CDR
2.00 CME
$0 FEE


This activity is designed to meet the needs of physicians, physician assistants, pharmacists, registered nurses, nurse practitioners, advance practice registered nurses, and registered dietitians with an interest in lipid management.

Online activity; Knowledge

At the conclusion of this activity, all participants should be able to:

  • Translate the historical indications and prescribing guidelines of statins;
  • Discuss how early outcomes trials and usage guidelines of novel therapies influenced current clinical practices in CVD prevention;
  • Summarize the potential for PCSK9 inhibitor indication expansion;
  • Analyze the use of omega-3 fatty acids in patient populations wherein outcomes studies have not been conducted;
  • Identify emerging lipid drug targets that may be important in ASCVD risk reduction;
  • Utilize specialized treatment strategies for the management of patients with multiple risk factors;
  • Discuss strategies to improve the knowledge, skills or performance of the healthcare team.

To obtain credit, a score of 80% or better on the post-test is required. This activity is offered at no cost to participants. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the post-test and evaluation, and have received a digital copy of your credit certificate.

For Pharmacists: Upon receipt of the completed activity evaluation form, transcript information will be available at within 4 weeks.

If you have any questions relating to the accreditation of this activity, please contact

This activity is supported by educational funding provided by Amgen and Sanofi US and Regeneron Pharmaceuticals.


CME/CE credit provided by the National Lipid Association

ACCME Jointly accredited
In support of improving patient care, The National Lipid Association is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

This enduring material is approved for 1 year from the date of original release, August 11, 2017 to August 11, 2018.

Physician Credit Designation Statement
The National Lipid Association designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only credit commensurate with the extent of their participation in this activity.

Physician Assistants
NCCPA accepts AMA PRA Category 1 Credits™ from organizations accredited by the ACCME.

The National Lipid Association is a Continuing Professional Education (CPE) Accredited Provider with the Commission on Dietetic Registration (CDR). Registered dietitians (RDs) and dietetic technicians, registered (DTRs) will receive 2.0 continuing professional education units (CPEUs) for completion of this program/ materials. CDR Accredited Provider #NL002.

Pharmacist Accreditation Statement
Universal Activity Number 0624-0000-17-046-H01-P (Knowledge)
This activity has been approved for 2.0 contact hour(s) (0.2 CEUs) of the Accreditation Council for Pharmacy.

The maximum number of hours awarded for this CE activity is 1.75 contact hours.

Joyce L. Ross, MSN, ANP, CRNP, CLS, FNLA
President, National Lipid Association
University of Pennsylvania Health System- Retired
Philadelphia, PA

Dave L. Dixon, PharmD, BCPS, CDE, FNLA
Associate Professor, Ambulatory Care
Vice-Chair of Clinical Services
Department of Pharmacotherapy and Outcomes Science
Virginia Commonwealth University
School of Pharmacy
Richmond, VA

Dean A. Bramlet, MD, FNLA*
Assistant Consulting Professor of Medicine
Duke University
Medical Director, Cardiovascular Diagnostic Center
The Heart & Lipid Institute of Florida
St. Petersburg, FL

Daniel J. Rader, MD, FNLA*
Seymour Gray Professor of Molecular Medicine
Chair, Department of Genetics
Chief, Division of Translational
Medicine and Human Genetics
Department of Medicine
Perelman School of Medicine
University of Pennsylvania
Philadelphia, PA

Joseph J. Saseen, PharmD, CLS, FNLA
Clinical Pharmacy & Family Medicine
University of Colorado Denver
Anschutz Medical Campus
Aurora, CO

*Denotes, Diplomate, American Board of Clinical Lipidology


Dean A. Bramlet, MD, FNLA
Speakers Bureau- Amarin, Astellas Pharma US, Kowa Pharmaceuticals America, Inc., Sanofi/Regeneron

David L. Dixon, PharmD, FNLA
Has nothing to disclose.

Daniel J. Rader, MD, FNLA
Consultant- Alnylam, Novartis, Pfizer

Advisory Board- Amarin
Consultant- Akcea, Kaneka America, Kastle Therapeutics
Speakers Bureau- Amarin, Amgen, Kaneka America, Practice Point, Regeneron, Sanofi
Speaker- AbbVie, Kowa Pharmaceuticals America

Joseph J. Saseen, PharmD, CLS, FNLA
Has nothing to disclose.

Staff Disclosures
NLA Staff
Has nothing to disclose.

NLA CME Committee Reviewers
Michael D. Shapiro, DO

Advisory Board- Alexion, Amgen, Bracco Consultant- Alexion, GE Health Care, Synta

This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

It is the policy of NLA to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. Planners, faculty, reviewers, and staff have disclosed any financial relationships with commercial interests as defined by the ACCME.

This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. The NLA specifically disclaims responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through reader’s misunderstanding of content.

The National Lipid Association acknowledges that permissions have been obtained for use of all copyrighted materials, including graphs, tables, pictures, and charts printed in this activity syllabus. Permissions have also been obtained from identifiable patients in photographs and other images, consistent with the DHHS HIPAA regulations for individual privacy.

Enduring webcast in production with Vindico Medical Education.

Click here for NLA’s Privacy Statement.